141 related articles for article (PubMed ID: 30103190)
1. Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease.
Lim JW; Kim SK; Choi SY; Kim DH; Gadhe CG; Lee HN; Kim HJ; Kim J; Cho SJ; Hwang H; Seong J; Jeong KS; Lee JY; Lim SM; Lee JW; Pae AN
Eur J Med Chem; 2018 Sep; 157():405-422. PubMed ID: 30103190
[TBL] [Abstract][Full Text] [Related]
2. Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2).
Ichihara Y; Fujimura R; Tsuneki H; Wada T; Okamoto K; Gouda H; Hirono S; Sugimoto K; Matsuya Y; Sasaoka T; Toyooka N
Eur J Med Chem; 2013 Apr; 62():649-60. PubMed ID: 23434638
[TBL] [Abstract][Full Text] [Related]
3. FcγRIIb-SHIP2 axis links Aβ to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model.
Kam TI; Park H; Gwon Y; Song S; Kim SH; Moon SW; Jo DG; Jung YK
Elife; 2016 Nov; 5():. PubMed ID: 27834631
[TBL] [Abstract][Full Text] [Related]
4. AS1949490, an inhibitor of 5'-lipid phosphatase SHIP2, promotes protein kinase C-dependent stabilization of brain-derived neurotrophic factor mRNA in cultured cortical neurons.
Tsuneki H; Yoshida H; Okamoto K; Yamaguchi M; Endo K; Nakano A; Tsuda M; Toyooka N; Wada T; Sasaoka T
Eur J Pharmacol; 2019 May; 851():69-79. PubMed ID: 30753865
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity.
Wada T; Sasaoka T; Funaki M; Hori H; Murakami S; Ishiki M; Haruta T; Asano T; Ogawa W; Ishihara H; Kobayashi M
Mol Cell Biol; 2001 Mar; 21(5):1633-46. PubMed ID: 11238900
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of SHIP2 activity inhibits cell migration and could prevent metastasis in breast cancer cells.
Ghosh S; Scozzaro S; Ramos AR; Delcambre S; Chevalier C; Krejci P; Erneux C
J Cell Sci; 2018 Aug; 131(16):. PubMed ID: 30012834
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the lipid phosphatase SHIP2 discovered by high-throughput affinity selection-mass spectrometry screening of combinatorial libraries.
Annis DA; Cheng CC; Chuang CC; McCarter JD; Nash HM; Nazef N; Rowe T; Kurzeja RJ; Shipps GW
Comb Chem High Throughput Screen; 2009 Sep; 12(8):760-71. PubMed ID: 19531013
[TBL] [Abstract][Full Text] [Related]
8. Small molecule targeting of SHIP1 and SHIP2.
Kerr WG; Pedicone C; Dormann S; Pacherille A; Chisholm JD
Biochem Soc Trans; 2020 Feb; 48(1):291-300. PubMed ID: 32049315
[TBL] [Abstract][Full Text] [Related]
9. The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain.
Soeda Y; Tsuneki H; Muranaka H; Mori N; Hosoh S; Ichihara Y; Kagawa S; Wang X; Toyooka N; Takamura Y; Uwano T; Nishijo H; Wada T; Sasaoka T
Mol Endocrinol; 2010 Oct; 24(10):1965-77. PubMed ID: 20829391
[TBL] [Abstract][Full Text] [Related]
10. Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation.
Hoekstra E; Das AM; Willemsen M; Swets M; Kuppen PJ; van der Woude CJ; Bruno MJ; Shah JP; Ten Hagen TL; Chisholm JD; Kerr WG; Peppelenbosch MP; Fuhler GM
Oncotarget; 2016 Nov; 7(45):73525-73540. PubMed ID: 27716613
[TBL] [Abstract][Full Text] [Related]
11. Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer's disease pathology progression.
Ando K; Küçükali F; Doeraene E; Nagaraj S; Antonelli EM; Thazin Htut M; Yilmaz Z; Kosa AC; Lopez-Guitierrez L; Quintanilla-Sánchez C; Aydin E; Ramos AR; Mansour S; Turbant S; Schurmans S; Sleegers K; Erneux C; Brion JP; Leroy K;
Acta Neuropathol; 2024 Jun; 147(1):94. PubMed ID: 38833073
[TBL] [Abstract][Full Text] [Related]
12. SHIP2: Structure, Function and Inhibition.
Thomas MP; Erneux C; Potter BV
Chembiochem; 2017 Feb; 18(3):233-247. PubMed ID: 27907247
[TBL] [Abstract][Full Text] [Related]
13. Regulation of PDGF-stimulated SHIP2 tyrosine phosphorylation and association with Shc in 3T3-L1 preadipocytes.
Artemenko Y; Gagnon A; Ibrahim S; Sorisky A
J Cell Physiol; 2007 Jun; 211(3):598-607. PubMed ID: 17219406
[TBL] [Abstract][Full Text] [Related]
14. Aβ modulates actin cytoskeleton via SHIP2-mediated phosphoinositide metabolism.
Lee HN; Sim KM; Kim H; Ju J; Pae AN; Park JB; Ryu H; Seong J
Sci Rep; 2019 Oct; 9(1):15557. PubMed ID: 31664099
[TBL] [Abstract][Full Text] [Related]
15. SHIP2 controls plasma membrane PI(4,5)P2 thereby participating in the control of cell migration in 1321 N1 glioblastoma cells.
Elong Edimo W; Ghosh S; Derua R; Janssens V; Waelkens E; Vanderwinden JM; Robe P; Erneux C
J Cell Sci; 2016 Mar; 129(6):1101-14. PubMed ID: 26826186
[TBL] [Abstract][Full Text] [Related]
16. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes.
Sasaoka T; Hori H; Wada T; Ishiki M; Haruta T; Ishihara H; Kobayashi M
Diabetologia; 2001 Oct; 44(10):1258-67. PubMed ID: 11692174
[TBL] [Abstract][Full Text] [Related]
17. Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice: SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis.
Grempler R; Zibrova D; Schoelch C; van Marle A; Rippmann JF; Redemann N
Diabetes; 2007 Sep; 56(9):2235-41. PubMed ID: 17596404
[TBL] [Abstract][Full Text] [Related]
18. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
Sasaoka T; Wada T; Tsuneki H
Pharmacol Ther; 2006 Dec; 112(3):799-809. PubMed ID: 16842857
[TBL] [Abstract][Full Text] [Related]
19. SHIPping out diabetes-Metformin, an old friend among new SHIP2 inhibitors.
Lehtonen S
Acta Physiol (Oxf); 2020 Jan; 228(1):e13349. PubMed ID: 31342643
[TBL] [Abstract][Full Text] [Related]
20. Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention.
Whitfield H; Hemmings AM; Mills SJ; Baker K; White G; Rushworth S; Riley AM; Potter BVL; Brearley CA
J Med Chem; 2021 Apr; 64(7):3813-3826. PubMed ID: 33724834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
